Week in Review: Beijing's Creat Offers $1.3 Billion for Biotest of Germany

Creat Group, a Beijing investment firm, offered $1.3 billion to acquire German blood plasma products maker Biotest; Tencent led a $200 million series D round in Haodaifu Online, a healthcare app; Shenzhen Royal Asset Management invested $23 million in a joint venture with Montreal's Prometic to develop three Prometic molecules in China; HEC ChangJiang Pharma will pay $20 million to South Korea's TaiGen Biotech for a 9% stake in their China hepatitis C JV; Kingdee, a Guangzhou mobile healthcare company, raised $14.5 million in a Series A round; GeneQuantum of Suzhou raised $5.8 million to advance its antibody drug conjugates toward IND filings; Qilu Pharma of Jinan and Korea's Alteogen agreed to co-develop and co-market an Alteogen Herceptin biosimilar in China; Suzhou's Innovent Biologics formed a global partnership with Korea's Hanmi Pharma to co-develop an immuno-oncology bispecific drug candidate; Shanghai's Luqa Pharma in-licensed China rights to a product that treats genito-urinary tract infections; Hunan Zhaotai Medical Group will test its CAR-T cancer drugs with New Zealand's Malaghan Institute; AstraZeneca was granted CFDA approval for Tagrisso, a third-gen EGFR inhibitor, to treat lung cancer; Asieris Pharma of China dosed the first bladder cancer patient in a pivotal Phase III trial of its lead candidate; Athenex, a New York State-Hong Kong biopharma, was approved to start US trials for its oral version of a generic chemotherapy; and JHL Biotech, a Taiwan-China biotech, dosed the first patient in a European trial of a biosimilar to MabThera/Rituxan. More details.... Stock Symbols; (DE: BIOG) (HK: 0700) (HK: 1558) (TWO: 4157) (KRX: 128940) (NYSE: AZN) (TWO: 6540) Share this with colleagues: // //